Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sixteen sheep were divided into four groups and were given saline, Escherichia coli endotoxin at 35 micrograms/kg0.75, dipyrone at 88 mg/kg0.75, or endotoxin and dipyrone intravenously. Plasma glucose concentrations, rectal temperature and
depression
of central nervous function were assessed at hourly intervals for 10 h and again at 24 h.
Dipyrone
had no effect on normal sheep but in sheep given endotoxin, it blocked the febrile response and partially blocked the
depression
effect upon the central nervous system without affecting the hypoglycaemic response.
...
PMID:Effects of dipyrone on endotoxin-induced fever, central nervous depression and hypoglycaemia in sheep. 638 72
Low levels of brain-derived neurotrophic factor (BDNF), a key regulator of synaptic plasticity, are associated with neurological diseases, including
depression
and Alzheimer's disease. Therefore, BDNF is a drug target for these diseases. Here we screened for inducers of neuronal Bdnf expression from a pharmacologically validated compound library using our recently developed screening assay based on luciferase activity in cultured cortical neurons. We identified 18 pharmacologically validated compounds, most of which were inferred to induce Bdnf expression by their validated pharmacological actions, such as G
s
-coupled receptor activation or neuronal excitation. Unexpectedly, the screening assay identified the antipyretic drug, dipyrone, to increase Bdnf expression.
Dipyrone
induced endogenous Bdnf expression by Ca
2+
influx evoked via L-type voltage-dependent Ca
2+
channels and the N-methyl-d-aspartate receptor, indicating that dipyrone induced activity-regulated Bdnf expression in neurons. However, dipyrone-induced Bdnf expression is independent of validated pharmacological effects. Although our screening assay is difficult to reveal how active compounds induce Bdnf expression, this method is convenient to identify inducers of Bdnf expression in primary neurons. Our screening assay evaluated neuronal BDNF induction and can be used to screen for drug re-positioning, as well as novel candidate drugs, for neurological diseases that have low levels of BDNF in the brain.
...
PMID:Identifying inducers of BDNF gene expression from pharmacologically validated compounds; antipyretic drug dipyrone increases BDNF mRNA in neurons. 3205 48
